Ventoxen is a generic version of VENCLEXTA which is a targeted cancer drug used to treat chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), and acute myeloid leukemia (AML) in certain adults.

It works by blocking BCL-2, a protein that helps cancer cells survive. In cancers like CLL and AML, BCL-2 is often overproduced, making the cancer cells resistant to treatment. By inhibiting BCL-2, Ventoxen helps restore the natural process of apoptosis (cell death), allowing cancer cells to die. This happens when the drug binds to BCL-2, releases pro-apoptotic proteins, and triggers a chain reaction that breaks down the cancer cells. Studies have shown that Ventoxen effectively kills tumor cells that rely on BCL-2 for survival.